Annual report pursuant to Section 13 and 15(d)

Grant Revenue (Details)

v3.21.1
Grant Revenue (Details) - USD ($)
 1 Months Ended 12 Months Ended 55 Months Ended
Dec. 31, 2019
Oct. 31, 2017
May 31, 2017
Jun. 30, 2016
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Grant Revenue              
Revenue         $ 2,947,969 $ 3,049,104  
Pelican Therapeutics, Inc.              
Grant Revenue              
Contribution to be made by Pelican         7,600,000   $ 7,600,000
Pelican Therapeutics, Inc. | Maximum              
Grant Revenue              
Amount of grant under Grant Contract with CIPRIT       $ 15,200,000      
Pelican Therapeutics, Inc. | Tranche 1              
Grant Revenue              
Revenue     $ 1,800,000        
Pelican Therapeutics, Inc. | Tranche 2              
Grant Revenue              
Revenue   $ 6,500,000          
Pelican Therapeutics, Inc. | Tranche 3              
Grant Revenue              
Revenue $ 5,400,000            
Pelican Therapeutics, Inc. | Grant revenue              
Grant Revenue              
Revenue             13,100,000
Grant receivable         $ 1,500,000   $ 1,500,000
Percentage of contribution         0.50%    
Pelican Therapeutics, Inc. | Grant revenue | Maximum              
Grant Revenue              
Royalty percentage after threshold is met         1.00%